These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

372 related articles for article (PubMed ID: 15160555)

  • 21. Economic impact of the introduction of an acellular pertussis vaccine in Canada: a 6-year analysis.
    Iskedjian M; De Serres G; Einarson TR; Walker JH
    Vaccine; 2010 Jan; 28(3):714-23. PubMed ID: 19895923
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Implementation of a pertussis immunization program in a teaching hospital: an argument for federally mandated pertussis vaccination of health care workers.
    Calderon M; Feja KN; Ford P; Frenkel LD; Gram A; Spector D; Tolan RW
    Am J Infect Control; 2008 Aug; 36(6):392-8. PubMed ID: 18675144
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Pertussis in adolescents and adults: should we vaccinate?
    Lee GM; Lebaron C; Murphy TV; Lett S; Schauer S; Lieu TA
    Pediatrics; 2005 Jun; 115(6):1675-84. PubMed ID: 15930232
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Re-emergence of pertussis: what are the solutions?
    Libster R; Edwards KM
    Expert Rev Vaccines; 2012 Nov; 11(11):1331-46. PubMed ID: 23249233
    [TBL] [Abstract][Full Text] [Related]  

  • 25. The effect of changing from whole-cell to acellular pertussis vaccine on the epidemiology of hospitalized children with pertussis in Canada.
    Bettinger JA; Halperin SA; De Serres G; Scheifele DW; Tam T
    Pediatr Infect Dis J; 2007 Jan; 26(1):31-5. PubMed ID: 17195702
    [TBL] [Abstract][Full Text] [Related]  

  • 26. [Old problems and new strategies in the fight against pertussis].
    Carlino C; Zaratti L; Franco E
    Ig Sanita Pubbl; 2013; 69(4):473-80. PubMed ID: 24091847
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Long-term follow-up of Swedish children vaccinated with acellular pertussis vaccines at 3, 5, and 12 months of age indicates the need for a booster dose at 5 to 7 years of age.
    Gustafsson L; Hessel L; Storsaeter J; Olin P
    Pediatrics; 2006 Sep; 118(3):978-84. PubMed ID: 16950988
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Pertussis before and after the introduction of acellular pertussis vaccines in Finland.
    Elomaa A; He Q; Minh NN; Mertsola J
    Vaccine; 2009 Sep; 27(40):5443-9. PubMed ID: 19628060
    [TBL] [Abstract][Full Text] [Related]  

  • 29. An investigation into the cause of the 1983 whooping cough epidemic in the Netherlands.
    van Gent M; de Greeff SC; van der Heide HG; Mooi FR
    Vaccine; 2009 Mar; 27(13):1898-903. PubMed ID: 19368769
    [TBL] [Abstract][Full Text] [Related]  

  • 30. A "new age" in pertussis prevention new opportunities through adult vaccination.
    Cortese MM; Baughman AL; Brown K; Srivastava P
    Am J Prev Med; 2007 Mar; 32(3):177-185. PubMed ID: 17296469
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Acellular pertussis vaccine composed of genetically inactivated pertussis toxin.
    Peppoloni S; Pizza M; De Magistris MT; Bartoloni A; Rappuoli R
    Physiol Chem Phys Med NMR; 1995; 27(4):355-61. PubMed ID: 8768791
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Cost-effectiveness analysis of various pertussis vaccination strategies primarily aimed at protecting infants in the Netherlands.
    Westra TA; de Vries R; Tamminga JJ; Sauboin CJ; Postma MJ
    Clin Ther; 2010 Aug; 32(8):1479-95. PubMed ID: 20728761
    [TBL] [Abstract][Full Text] [Related]  

  • 33. [Assessment of postvaccinal response in children past pertussis].
    Grzybowska K; Przybyszewski M; Banasik M; Płaneta-Małecka I; Zeman K
    Wiad Lek; 2006; 59(11-12):819-22. PubMed ID: 17427498
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Control of pertussis--lessons learnt from a 10-year surveillance programme in Sweden.
    Carlsson RM; Trollfors B
    Vaccine; 2009 Sep; 27(42):5709-18. PubMed ID: 19679218
    [TBL] [Abstract][Full Text] [Related]  

  • 35. [Safety surveillance in the National Vaccination Programme; fewer adverse events with the DTP-IPV-Hib vaccine after the transition to an acellular pertussis component in 2005].
    van der Maas NA; David S; Kemmeren JM; Vermeer-de Bondt PE
    Ned Tijdschr Geneeskd; 2007 Dec; 151(49):2732-7. PubMed ID: 18225797
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Is pertussis a frequent cause of cough in adolescents and adults? Should routine pertussis immunization be recommended?
    Edwards KM
    Clin Infect Dis; 2001 Jun; 32(12):1698-9. PubMed ID: 11360209
    [No Abstract]   [Full Text] [Related]  

  • 37. Acellular pertussis vaccines in Japan: past, present and future.
    Watanabe M; Nagai M
    Expert Rev Vaccines; 2005 Apr; 4(2):173-84. PubMed ID: 15889991
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Making vaccination policy: the experience with rubella.
    Parkman PD
    Clin Infect Dis; 1999 Jun; 28 Suppl 2():S140-6. PubMed ID: 10447033
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Reactogenicity of infant whole cell pertussis combination vaccine compared with acellular pertussis vaccines with or without simultaneous pneumococcal vaccine in the Netherlands.
    David S; Vermeer-de Bondt PE; van der Maas NA
    Vaccine; 2008 Oct; 26(46):5883-7. PubMed ID: 18775463
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Impact of routine vaccination with a pertussis toxoid vaccine in Denmark.
    Hviid A; Stellfeld M; Andersen PH; Wohlfahrt J; Melbye M
    Vaccine; 2004 Sep; 22(27-28):3530-4. PubMed ID: 15315832
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 19.